108 related articles for article (PubMed ID: 38754731)
1. The journey of determining PD-L1 expression in muscle-invasive urothelial carcinoma.
Algaba F
Actas Urol Esp (Engl Ed); 2024 May; ():. PubMed ID: 38754731
[No Abstract] [Full Text] [Related]
2. PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.
Gupta G; Pasricha S; Kamboj M; Sharma A; Nayana NS; Durga G; Sharma A; Rawal S; Meh A
Indian J Pathol Microbiol; 2022; 65(4):839-843. PubMed ID: 36308190
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
[TBL] [Abstract][Full Text] [Related]
4. Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
Sungu N; Kıran MM
Pol J Pathol; 2023; 74(3):161-170. PubMed ID: 37955535
[TBL] [Abstract][Full Text] [Related]
5. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
[TBL] [Abstract][Full Text] [Related]
6. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors.
Plage H; Furlano K; Hofbauer S; Weinberger S; Ralla B; Franz A; Fendler A; de Martino M; Roßner F; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Zecha H; Minner S; Simon R; Sauter G; Weischenfeldt J; Klatte T; Schlomm T; Horst D; Schallenberg S
BMC Urol; 2024 Apr; 24(1):96. PubMed ID: 38658905
[TBL] [Abstract][Full Text] [Related]
9. Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma.
Huang TH; Cheng W; Wang YH
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33807802
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Ding X; Chen Q; Yang Z; Li J; Zhan H; Lu N; Chen M; Yang Y; Wang J; Yang D
Cancer Manag Res; 2019; 11():4171-4184. PubMed ID: 31190987
[No Abstract] [Full Text] [Related]
11. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Bajorin DF; Witjes JA; Gschwend JE; Schenker M; Valderrama BP; Tomita Y; Bamias A; Lebret T; Shariat SF; Park SH; Ye D; Agerbaek M; Enting D; McDermott R; Gajate P; Peer A; Milowsky MI; Nosov A; Neif Antonio J; Tupikowski K; Toms L; Fischer BS; Qureshi A; Collette S; Unsal-Kacmaz K; Broughton E; Zardavas D; Koon HB; Galsky MD
N Engl J Med; 2021 Jun; 384(22):2102-2114. PubMed ID: 34077643
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype.
Kim B; Lee C; Kim YA; Moon KC
Front Oncol; 2020; 10():527385. PubMed ID: 33365265
[TBL] [Abstract][Full Text] [Related]
13. The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma.
Erlmeier F; Seitz AK; Hatzichristodoulou G; Stecher L; Retz M; Gschwend JE; Weichert W; Kübler HR; Horn T
Bladder Cancer; 2016 Oct; 2(4):425-432. PubMed ID: 28035323
[No Abstract] [Full Text] [Related]
14. Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Perrone F; Nicolai N; Catanzaro M; Biasoni D; Torelli T; Piva L; Stagni S; Salvioni R; Mariani L; Colecchia M
Clin Genitourin Cancer; 2018 Apr; 16(2):e403-e410. PubMed ID: 29111177
[TBL] [Abstract][Full Text] [Related]
15. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.
Chen X; Chen H; Lin R; Li Y; Guo Y; Chen Q; Zhang Y; Cai G; Hu M; Chen G
J Clin Pathol; 2023 Dec; 77(1):61-67. PubMed ID: 36319076
[TBL] [Abstract][Full Text] [Related]
16. The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma.
Hlaing STM; Damayanti P; Zin Aung K; Tsukino H; Hinoura T; Kuroda Y
Cureus; 2023 Nov; 15(11):e48120. PubMed ID: 38046711
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience.
Nasr S; Haddad FG; Khazen J; Kattan J; Trak-Smayra V
BMC Cancer; 2023 Sep; 23(1):817. PubMed ID: 37658290
[TBL] [Abstract][Full Text] [Related]
18. Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas.
Kumar U; Anthony ML; Sahai R; Mittal A; Durgapal P; Kishore S
J Lab Physicians; 2022 Jun; 14(2):197-201. PubMed ID: 35982880
[No Abstract] [Full Text] [Related]
19. PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.
Pierconti F; Raspollini MR; Martini M; Larocca LM; Bassi PF; Bientinesi R; Baroni G; Minervini A; Petracco G; Pini GM; Patriarca C
Virchows Arch; 2020 Aug; 477(2):269-277. PubMed ID: 32034486
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma.
Kang SY; Heo YJ; Kwon GY; Kim KM
Front Oncol; 2022; 12():856444. PubMed ID: 35574404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
